Skip to main content
Top
Published in: BMC Public Health 1/2020

Open Access 01-12-2020 | Care | Research article

Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment

Authors: Caroline O’Keefe-Markman, Kristina Dawn Lea, Christopher McCabe, Elaine Hyshka, Tania Bubela

Published in: BMC Public Health | Issue 1/2020

Login to get access

Abstract

Background

Health care system decision makers face challenges in allocating resources for screening, diagnosis and treatment of hepatitis C. Approximately 240,000 individuals are infected with the hepatitis C virus (HCV) in Canada. Populations most affected by HCV include Indigenous people, people who inject drugs, immigrants and homeless or incarcerated populations as well as those born between 1946 and 1965. Curative but expensive drug regimens of novel direct acting antivirals (DAAs) are available. We aim to identify social values from academic literature for inclusion in health technology assessments.

Methods

We conducted a scoping review of academic literature to identify and analyze the social values and evidence-based recommendations for screening, diagnosis and treatment of HCV in Canada. After applying inclusion/exclusion criteria, we abstracted: type of intervention(s), population(s) affected, study location, screening methods, diagnostics and treatments. We then abstracted and applied qualitative codes for social values. We extracted social value statements and clustered them into one of 4 categories: (1) equity and justice, (2) duty to provide care, (3) maximization of population benefit, and (4) individual versus community interests.

Results

One hundred and eighteen articles met our inclusion criteria on screening, diagnosis and treatment of HCV in Canada. Of these, 54 (45.8%) discussed screening, 4 (3.4%) discussed diagnosis and 60 (50.8%) discussed treatment options. Most articles discussed the general population and other non-vulnerable populations. Articles that discussed vulnerable populations focused on people who inject drugs. We coded 1243 statements, most of which fell into the social value categories of equity and justice, duty to provide care and maximization of population benefit.

Conclusion

The academic literature identified an expanded set of social values to be taken into account by resource allocation decision makers in financially constrained environments. In the context of hepatitis C, authors called for greater consideration of equity and justice and the duty to provide care in making evidence-based recommendations for screening, diagnosis and treatment for different populations and in different settings that also account for individual and community interests.
Literature
1.
go back to reference Culyer AJ, Cookson R. The humble economist: Tony Culyer on health. Health Care and Social Decision Making: University of York; 2012. Culyer AJ, Cookson R. The humble economist: Tony Culyer on health. Health Care and Social Decision Making: University of York; 2012.
3.
4.
go back to reference Paulden M, Stafinski T, Menon D, McCabe C. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics. 2015;33(3):255–69.PubMedCrossRef Paulden M, Stafinski T, Menon D, McCabe C. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics. 2015;33(3):255–69.PubMedCrossRef
5.
go back to reference Menon D, Stafinski T. Health technology assessment in Canada: 20 years strong? Value Health. 2009;12:S14–9.PubMedCrossRef Menon D, Stafinski T. Health technology assessment in Canada: 20 years strong? Value Health. 2009;12:S14–9.PubMedCrossRef
6.
go back to reference Menzel P, Gold MR, Nord E, Pinto-Prades JL, Richardson J, Ubel P. Towarda broader view of values in cost-effectiveness analysis of health. Hastings Cent Rep. 1999;29(3):7–15.PubMedCrossRef Menzel P, Gold MR, Nord E, Pinto-Prades JL, Richardson J, Ubel P. Towarda broader view of values in cost-effectiveness analysis of health. Hastings Cent Rep. 1999;29(3):7–15.PubMedCrossRef
7.
go back to reference Ubel PA, Richardson J, Menzel P. Societal value, the person trade-off, and the dilemma of whose values to measure for cost-effectiveness analysis. Health Econ. 2000;9(2):127–36.PubMedCrossRef Ubel PA, Richardson J, Menzel P. Societal value, the person trade-off, and the dilemma of whose values to measure for cost-effectiveness analysis. Health Econ. 2000;9(2):127–36.PubMedCrossRef
8.
go back to reference Blomqvist A, Busby C, Husereau D. “Capturing value from health Technologies in Lean Times.” CD Howe Institute Commentary; 2013. p. 396. Blomqvist A, Busby C, Husereau D. “Capturing value from health Technologies in Lean Times.” CD Howe Institute Commentary; 2013. p. 396.
9.
go back to reference Berglas S, et al. Patients’ perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review. Res Involv Engagem. 2016;2(1):21.PubMedPubMedCentralCrossRef Berglas S, et al. Patients’ perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review. Res Involv Engagem. 2016;2(1):21.PubMedPubMedCentralCrossRef
10.
go back to reference Chen W, Wassenaar HJ. An approach to decision-based design with discrete choice analysis for demand modeling. J Mech Des. 2003;125(3):490–7.CrossRef Chen W, Wassenaar HJ. An approach to decision-based design with discrete choice analysis for demand modeling. J Mech Des. 2003;125(3):490–7.CrossRef
11.
go back to reference Wailoo A, Tsuchiya A, McCabe C. Weighting must wait. Pharmacoeconomics. 2009;27(12):983–9 Weber, C. (2013). Point-of-care tests for infection control: should rapid testing be in the laboratory or at the front line?. J Hosp Infect, 85(1), 1–7.PubMedCrossRef Wailoo A, Tsuchiya A, McCabe C. Weighting must wait. Pharmacoeconomics. 2009;27(12):983–9 Weber, C. (2013). Point-of-care tests for infection control: should rapid testing be in the laboratory or at the front line?. J Hosp Infect, 85(1), 1–7.PubMedCrossRef
12.
go back to reference Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs. 2013;22(9):1107–21.PubMedCrossRef Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs. 2013;22(9):1107–21.PubMedCrossRef
13.
go back to reference Grady BP, et al. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis. 2013;57(suppl_2):S105–10.PubMedCrossRef Grady BP, et al. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis. 2013;57(suppl_2):S105–10.PubMedCrossRef
14.
go back to reference Martin NK, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5):1598–609.PubMedCrossRef Martin NK, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5):1598–609.PubMedCrossRef
15.
go back to reference Montaner JSG, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population- based study. Lancet. 2010;376(9740):532–9.PubMedPubMedCentralCrossRef Montaner JSG, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population- based study. Lancet. 2010;376(9740):532–9.PubMedPubMedCentralCrossRef
17.
go back to reference Childress JF, Beauchamp TL. Principles of biomedical ethics. USA: Oxford University Press; 2001. Childress JF, Beauchamp TL. Principles of biomedical ethics. USA: Oxford University Press; 2001.
19.
20.
go back to reference Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs. 2013;18(4):461–75.PubMedCrossRef Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs. 2013;18(4):461–75.PubMedCrossRef
22.
go back to reference Canadian Task Force on Preventive Health Care. Recommendations on hepatitis C screening for adults. Can Med Assoc J. 2017;189(16):E594–604.CrossRef Canadian Task Force on Preventive Health Care. Recommendations on hepatitis C screening for adults. Can Med Assoc J. 2017;189(16):E594–604.CrossRef
23.
go back to reference Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.CrossRef Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.CrossRef
24.
go back to reference Arneson RJ. Equality of opportunity: derivative not fundamental. J Soc Philos. 2013;44(4):316–30.CrossRef Arneson RJ. Equality of opportunity: derivative not fundamental. J Soc Philos. 2013;44(4):316–30.CrossRef
25.
go back to reference Gibson D. The Canada Health Act and the Constitution. Health LJ. 1996;4:1. Gibson D. The Canada Health Act and the Constitution. Health LJ. 1996;4:1.
26.
go back to reference Bentham J. Introduction to moral principles; 2011. Bentham J. Introduction to moral principles; 2011.
27.
go back to reference Holland S. Public health ethics (2nd ed.): Wiley; 2007. Holland S. Public health ethics (2nd ed.): Wiley; 2007.
28.
go back to reference Belsham W. Essays, Philosophical, Historical and Literary.[By W. Belsham.], vol. 1; 1789. C. Dilly Belsham W. Essays, Philosophical, Historical and Literary.[By W. Belsham.], vol. 1; 1789. C. Dilly
29.
go back to reference Mill JS. Remarks on Bentham’s philosophy; 2008. Mill JS. Remarks on Bentham’s philosophy; 2008.
30.
go back to reference Singer P, editor. A Companion to Ethics: Wiley; 2013. Singer P, editor. A Companion to Ethics: Wiley; 2013.
31.
go back to reference Spittal PM, Pearce ME, Chavoshi N, Christian WM, Moniruzzaman A, Teegee M, Schechter MT. The cedar project: high incidence of HCV infections in a longitudinal study of young aboriginal people who use drugs in two Canadian cities. BMC Public Health. 2012;12(1):632.PubMedPubMedCentralCrossRef Spittal PM, Pearce ME, Chavoshi N, Christian WM, Moniruzzaman A, Teegee M, Schechter MT. The cedar project: high incidence of HCV infections in a longitudinal study of young aboriginal people who use drugs in two Canadian cities. BMC Public Health. 2012;12(1):632.PubMedPubMedCentralCrossRef
32.
go back to reference Goldman M, Juodvalkis S, Gill P, Spurll G. Hepatitis C lookback. Transfus Med Rev. 1998;12(2):84–93.PubMedCrossRef Goldman M, Juodvalkis S, Gill P, Spurll G. Hepatitis C lookback. Transfus Med Rev. 1998;12(2):84–93.PubMedCrossRef
33.
go back to reference Spittal PM, Pearce ME, Patel SH, Chavoshi N, Teegee M, Schechter MT. For the cedar project Partnership, Moniruzzaman, the cedar project: correlates of attempted suicide among young aboriginal people who use injection and non-injection drugs in two Canadian cities. Int J Circumpolar Health. 2009;68(3):261–73.PubMedCrossRef Spittal PM, Pearce ME, Patel SH, Chavoshi N, Teegee M, Schechter MT. For the cedar project Partnership, Moniruzzaman, the cedar project: correlates of attempted suicide among young aboriginal people who use injection and non-injection drugs in two Canadian cities. Int J Circumpolar Health. 2009;68(3):261–73.PubMedCrossRef
34.
go back to reference Correctional Service Canada. Testing and Treatment for Human Immunodeficiency Virus and Hepatitis C Virus Infections among Canadian Federal Inmates 2010; www.csc-scc.gc.ca. Correctional Service Canada. Testing and Treatment for Human Immunodeficiency Virus and Hepatitis C Virus Infections among Canadian Federal Inmates 2010; www.​csc-scc.​gc.​ca.
35.
go back to reference Fralick M. Screening urged for hepatitis C but drug costs are prohibitive.; 2014. p. 329. Fralick M. Screening urged for hepatitis C but drug costs are prohibitive.; 2014. p. 329.
36.
go back to reference Werb D, Wood E, Kerr T, Hershfield N, Palmer RW, Remis RS. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006–2026. Int J Drug Policy. 2011;22(1):70–6.PubMedCrossRef Werb D, Wood E, Kerr T, Hershfield N, Palmer RW, Remis RS. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006–2026. Int J Drug Policy. 2011;22(1):70–6.PubMedCrossRef
37.
go back to reference Hill WD, Butt G, Alvarez M, Krajden M. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol Hepatol. 2008;22(1):27–32. Hill WD, Butt G, Alvarez M, Krajden M. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol Hepatol. 2008;22(1):27–32.
38.
go back to reference Doucette K, Robson V, Shafran S, Kunimoto D. Improving access to care by allowing self-referral to a hepatitis C clinic. Can J Gastroenterol Hepatol. 2009;23(6):421–4. Doucette K, Robson V, Shafran S, Kunimoto D. Improving access to care by allowing self-referral to a hepatitis C clinic. Can J Gastroenterol Hepatol. 2009;23(6):421–4.
39.
go back to reference Reindollar RW. Hepatitis C and the correctional population. Am J Med. 1999;107(6):100–3.CrossRef Reindollar RW. Hepatitis C and the correctional population. Am J Med. 1999;107(6):100–3.CrossRef
40.
go back to reference Farley J, Vasdev S, Fischer B, Haydon E, Rehm J, Farley TA. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health. 2005;95(10):1737–9.PubMedPubMedCentralCrossRef Farley J, Vasdev S, Fischer B, Haydon E, Rehm J, Farley TA. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health. 2005;95(10):1737–9.PubMedPubMedCentralCrossRef
41.
go back to reference De P, Cox J, Boivin JF, Platt RW, Jolly AM, Alexander PE. HIV and HCV discordant injecting partners and their association to drug equipment sharing. Scand J Infect Dis. 2009;41(3):206–14.PubMedPubMedCentralCrossRef De P, Cox J, Boivin JF, Platt RW, Jolly AM, Alexander PE. HIV and HCV discordant injecting partners and their association to drug equipment sharing. Scand J Infect Dis. 2009;41(3):206–14.PubMedPubMedCentralCrossRef
42.
go back to reference Cunningham EB, Jacka B, DeBeck K, Applegate TL, Harrigan PR, Krajden M, et al. Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. Drug Alcohol Depend. 2015;152:272–6.PubMedPubMedCentralCrossRef Cunningham EB, Jacka B, DeBeck K, Applegate TL, Harrigan PR, Krajden M, et al. Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. Drug Alcohol Depend. 2015;152:272–6.PubMedPubMedCentralCrossRef
43.
go back to reference Paterson BL, Butt G, McGuinness L, Moffat B. The construction of hepatitis C as a chronic illness. Clin Nurs Res. 2006;15(3):209–24.PubMedCrossRef Paterson BL, Butt G, McGuinness L, Moffat B. The construction of hepatitis C as a chronic illness. Clin Nurs Res. 2006;15(3):209–24.PubMedCrossRef
44.
go back to reference Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008;93(1):141–7.PubMedCrossRef Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008;93(1):141–7.PubMedCrossRef
45.
go back to reference Roy KM, Hutchinson SJ, Wadd S, Taylor A, Cameron SO, Burns S, Goldberg DJ. Hepatitis C virus infection among injecting drug users: a review of prevalence and incidence data and the methods used to generate them. Epidemiol Infect. 2007;135(3):433–42.PubMedCrossRef Roy KM, Hutchinson SJ, Wadd S, Taylor A, Cameron SO, Burns S, Goldberg DJ. Hepatitis C virus infection among injecting drug users: a review of prevalence and incidence data and the methods used to generate them. Epidemiol Infect. 2007;135(3):433–42.PubMedCrossRef
46.
go back to reference Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of chronic hepatitis C: consensus guidelines from the Canadian association for the study of the liver. Can J Gastroenterol. 2012;26(6):359–75.PubMedPubMedCentralCrossRef Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of chronic hepatitis C: consensus guidelines from the Canadian association for the study of the liver. Can J Gastroenterol. 2012;26(6):359–75.PubMedPubMedCentralCrossRef
47.
go back to reference Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009;3(4):353–67.PubMedCrossRef Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009;3(4):353–67.PubMedCrossRef
48.
go back to reference Artenie AA, Jutras-Aswad D, Roy É, Zang G, Bamvita JM, Lévesque A, Bruneau J. Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement. J Viral Hepat. 2015;22(10):792–9.PubMedCrossRef Artenie AA, Jutras-Aswad D, Roy É, Zang G, Bamvita JM, Lévesque A, Bruneau J. Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement. J Viral Hepat. 2015;22(10):792–9.PubMedCrossRef
49.
go back to reference Coward S, Leggett L, Kaplan GG, Clement F. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations. BMJ Open. 2016;6(9):e011821.PubMedPubMedCentralCrossRef Coward S, Leggett L, Kaplan GG, Clement F. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations. BMJ Open. 2016;6(9):e011821.PubMedPubMedCentralCrossRef
50.
go back to reference Alavi M, Raffa JD, Deans GD, Lai C, Krajden M, Dore GJ, Grebely J. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int. 2014;34(8):1198–206.PubMedCrossRef Alavi M, Raffa JD, Deans GD, Lai C, Krajden M, Dore GJ, Grebely J. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int. 2014;34(8):1198–206.PubMedCrossRef
51.
go back to reference Bruggmann P. Accessing hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat. 2012;19(12):829–35.PubMedCrossRef Bruggmann P. Accessing hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat. 2012;19(12):829–35.PubMedCrossRef
52.
go back to reference Grebely J, Devlaming S, Duncan F, Viljoen M, Conway B. Current approaches to HCV infection in current and former injection drug users. J Addict Dis. 2008;27(2):25–35.PubMedCrossRef Grebely J, Devlaming S, Duncan F, Viljoen M, Conway B. Current approaches to HCV infection in current and former injection drug users. J Addict Dis. 2008;27(2):25–35.PubMedCrossRef
53.
go back to reference Chu S. Clean switch: the case for prison needle and syringe programs. HIV AIDS Policy Law Rev. 2009;14(2):5–19.PubMed Chu S. Clean switch: the case for prison needle and syringe programs. HIV AIDS Policy Law Rev. 2009;14(2):5–19.PubMed
54.
go back to reference Buxton JA, Yu A, Kim PH, Spinelli JJ, Kuo M, Alvarez M, et al. HCV co-infection in HIV positive population in British Columbia, Canada. BMC Public Health. 2010;10(1):225.PubMedPubMedCentralCrossRef Buxton JA, Yu A, Kim PH, Spinelli JJ, Kuo M, Alvarez M, et al. HCV co-infection in HIV positive population in British Columbia, Canada. BMC Public Health. 2010;10(1):225.PubMedPubMedCentralCrossRef
55.
go back to reference Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG. Cost-effectiveness of strategies for testing current hepatitis C virus infection. Hepatology. 2015;62(5):1396–404.PubMedCrossRef Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG. Cost-effectiveness of strategies for testing current hepatitis C virus infection. Hepatology. 2015;62(5):1396–404.PubMedCrossRef
56.
go back to reference Weber C. Point-of-care tests for infection control: should rapid testing be in the laboratory or at the front line? J Hosp Infect. 2013;85(1):1–7.CrossRef Weber C. Point-of-care tests for infection control: should rapid testing be in the laboratory or at the front line? J Hosp Infect. 2013;85(1):1–7.CrossRef
57.
go back to reference McPartlin DA, O’Kennedy RJ. Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: potential and limitations. Expert Rev Mol Diagn. 2014;14(8):979–98.PubMedCrossRef McPartlin DA, O’Kennedy RJ. Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: potential and limitations. Expert Rev Mol Diagn. 2014;14(8):979–98.PubMedCrossRef
58.
go back to reference Henderson C, Madden A, Kelsall J. ‘Beyond the willing & the waiting’—the role of peer-based approaches in hepatitis C diagnosis & treatment. Int J Drug Policy. 2017;50:111–5.PubMedCrossRef Henderson C, Madden A, Kelsall J. ‘Beyond the willing & the waiting’—the role of peer-based approaches in hepatitis C diagnosis & treatment. Int J Drug Policy. 2017;50:111–5.PubMedCrossRef
59.
go back to reference Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin Infect Dis. 2015;60(12):1829–36.PubMedCrossRef Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin Infect Dis. 2015;60(12):1829–36.PubMedCrossRef
60.
61.
go back to reference Smyth D, Webster D. Hepatitis C virus infection: accessing drug treatment. Can Med Assoc J. 2015;187(15):1113–4.CrossRef Smyth D, Webster D. Hepatitis C virus infection: accessing drug treatment. Can Med Assoc J. 2015;187(15):1113–4.CrossRef
62.
go back to reference Jagpreet C, He T, Lopez-Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics. 2016;34(6):551–67.CrossRef Jagpreet C, He T, Lopez-Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics. 2016;34(6):551–67.CrossRef
63.
go back to reference Conway B, et al. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin Infect Dis. 2005;41(Supplement 1):S73–8.PubMedCrossRef Conway B, et al. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin Infect Dis. 2005;41(Supplement 1):S73–8.PubMedCrossRef
64.
go back to reference Smyth DJ, Webster D, Barrett L, MacMillan M, McKnight L, Schweiger F. Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guide. Can J Gastroenterol Hepatol. 2014;28(10):529–34.PubMedPubMedCentralCrossRef Smyth DJ, Webster D, Barrett L, MacMillan M, McKnight L, Schweiger F. Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guide. Can J Gastroenterol Hepatol. 2014;28(10):529–34.PubMedPubMedCentralCrossRef
65.
go back to reference Muhlbacher Sanyal C, Ingram EL, Sketris IS, Peltekian KM, Kirkland S. Coping strategies used by patients infected with hepatitis C virus who are facing medication costs. Can J Hosp Pharm. 2011;64(2):131. Muhlbacher Sanyal C, Ingram EL, Sketris IS, Peltekian KM, Kirkland S. Coping strategies used by patients infected with hepatitis C virus who are facing medication costs. Can J Hosp Pharm. 2011;64(2):131.
66.
go back to reference Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, O'shaughnessy MV. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Can Med Assoc J. 2001;165(7):889–95. Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, O'shaughnessy MV. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Can Med Assoc J. 2001;165(7):889–95.
67.
go back to reference Fischer B, Haydon E, Rehm J, Krajden M, Reimer J. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach-the case study of Canada. J Urban Health. 2004;81(3):428–47.PubMedPubMedCentralCrossRef Fischer B, Haydon E, Rehm J, Krajden M, Reimer J. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach-the case study of Canada. J Urban Health. 2004;81(3):428–47.PubMedPubMedCentralCrossRef
68.
go back to reference Leonard L, DeRubeis E, Pelude L, Medd E, Birkett N, Seto J. “I inject less as I have easier access to pipes”: injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed. Int J Drug Policy. 2008;19(3):255–64.PubMedCrossRef Leonard L, DeRubeis E, Pelude L, Medd E, Birkett N, Seto J. “I inject less as I have easier access to pipes”: injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed. Int J Drug Policy. 2008;19(3):255–64.PubMedCrossRef
69.
go back to reference Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, Tyndall MW. Rationale for evaluating North America’s first medically supervised safer- injecting facility. Lancet Infect Dis. 2004;4(5):301–6.PubMedCrossRef Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, Tyndall MW. Rationale for evaluating North America’s first medically supervised safer- injecting facility. Lancet Infect Dis. 2004;4(5):301–6.PubMedCrossRef
70.
go back to reference Newman AI, Beckstead S, Beking D, Finch S, Knorr T, Lynch C, et al. Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health center. Can J Gastroenterol Hepatol. 2013;24(4):217–23. Newman AI, Beckstead S, Beking D, Finch S, Knorr T, Lynch C, et al. Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health center. Can J Gastroenterol Hepatol. 2013;24(4):217–23.
71.
go back to reference Kapeluto JE, Kadatz M, Wormsbecker A, Sidhu K, Yoshida EM. Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: a pilot project undertaken at the Vancouver general hospital. Can J Gastroenterol Hepatol. 2014;28(6):315–8.PubMedPubMedCentralCrossRef Kapeluto JE, Kadatz M, Wormsbecker A, Sidhu K, Yoshida EM. Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: a pilot project undertaken at the Vancouver general hospital. Can J Gastroenterol Hepatol. 2014;28(6):315–8.PubMedPubMedCentralCrossRef
72.
go back to reference Macneil J, Pauly B. Needle exchange as a safe haven in an unsafe world. Drug Alcohol Rev. 2011;30(1):26–32.PubMedCrossRef Macneil J, Pauly B. Needle exchange as a safe haven in an unsafe world. Drug Alcohol Rev. 2011;30(1):26–32.PubMedCrossRef
74.
go back to reference Stoller N. Space, place and movement as aspects of health care in three women’s prisons. Soc Sci Med. 2003;56(11):2263–75.PubMedCrossRef Stoller N. Space, place and movement as aspects of health care in three women’s prisons. Soc Sci Med. 2003;56(11):2263–75.PubMedCrossRef
75.
go back to reference Craib KJ, Spittal PM, Patel SH, Christian WM, Moniruzzaman AKM, Pearce ME, et al. Prevalence and incidence of hepatitis C virus infection among aboriginal young people who use drugs: results from the cedar project. Open Med. 2009;3(4):e220.PubMedPubMedCentral Craib KJ, Spittal PM, Patel SH, Christian WM, Moniruzzaman AKM, Pearce ME, et al. Prevalence and incidence of hepatitis C virus infection among aboriginal young people who use drugs: results from the cedar project. Open Med. 2009;3(4):e220.PubMedPubMedCentral
76.
77.
go back to reference Wu HX, Wu J, Wong T, Andonov A, Li Q, Dinner K, et al. Incidence and risk factors for newly acquired hepatitis C virus infection among aboriginal versus non- aboriginal Canadians in six regions, 1999–2004. Eur J Clin Microbiol Infect Dis. 2007;26(3):167–74.PubMedCrossRef Wu HX, Wu J, Wong T, Andonov A, Li Q, Dinner K, et al. Incidence and risk factors for newly acquired hepatitis C virus infection among aboriginal versus non- aboriginal Canadians in six regions, 1999–2004. Eur J Clin Microbiol Infect Dis. 2007;26(3):167–74.PubMedCrossRef
78.
go back to reference Dell DE, Hopkins C. Resiliency and holistic inhalant abuse treatment. Int J Indigen Health. 2005;2(1):4. Dell DE, Hopkins C. Resiliency and holistic inhalant abuse treatment. Int J Indigen Health. 2005;2(1):4.
79.
go back to reference Bowker SL, Smith LJ, Rosychuk RJ, Preiksaitis JK. A review of general hepatitis C virus lookbacks in Canada. Vox Sang. 2004;86(1):21–7.PubMedCrossRef Bowker SL, Smith LJ, Rosychuk RJ, Preiksaitis JK. A review of general hepatitis C virus lookbacks in Canada. Vox Sang. 2004;86(1):21–7.PubMedCrossRef
80.
go back to reference Mathias R. The Krever commission and public health (editorial). Can J Public Health. 1998;89(1):7.CrossRef Mathias R. The Krever commission and public health (editorial). Can J Public Health. 1998;89(1):7.CrossRef
81.
go back to reference Callum JL, Pinkerton PH, Coovadia AS, Thomson AE, Dewsbury F. An evaluation of the process and costs associated with targeted lookbacks for HCV and general notification of transfusion recipients. Transfusion. 2000;40(10):1169–75.PubMedCrossRef Callum JL, Pinkerton PH, Coovadia AS, Thomson AE, Dewsbury F. An evaluation of the process and costs associated with targeted lookbacks for HCV and general notification of transfusion recipients. Transfusion. 2000;40(10):1169–75.PubMedCrossRef
82.
go back to reference Angelotta C, McKoy JM, Fisher MJ, Buffie CG, Barfi K, Ramsey G, et al. Legal, financial, and public health consequences of transfusion-transmitted hepatitis C virus in persons with haemophilia. Vox Sang. 2007;93(2):159–65.PubMedCrossRef Angelotta C, McKoy JM, Fisher MJ, Buffie CG, Barfi K, Ramsey G, et al. Legal, financial, and public health consequences of transfusion-transmitted hepatitis C virus in persons with haemophilia. Vox Sang. 2007;93(2):159–65.PubMedCrossRef
83.
go back to reference Thein HH, Yi Q, Heathcote EJ, Krahn MD. Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort. J Viral Hepat. 2009;16(11):802–13.PubMedCrossRef Thein HH, Yi Q, Heathcote EJ, Krahn MD. Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort. J Viral Hepat. 2009;16(11):802–13.PubMedCrossRef
84.
go back to reference Krahn M, et al. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Mak. 2004;24(1):20–9.CrossRef Krahn M, et al. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Mak. 2004;24(1):20–9.CrossRef
85.
go back to reference Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 consensus guidelines from the Canadian association for the study of the liver. Can J Gastroenterol Hepatol. 2015;29(1):19–34.PubMedPubMedCentralCrossRef Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 consensus guidelines from the Canadian association for the study of the liver. Can J Gastroenterol Hepatol. 2015;29(1):19–34.PubMedPubMedCentralCrossRef
86.
go back to reference Brunings P, Klar S, Butt G, Nijkamp MD, Buxton JA. “It's a big part of our lives”: a qualitative study defining quality of hepatitis C care from the patient's perspective. Gastroenterol Nurs. 2013;36(4):249–57.PubMedCrossRef Brunings P, Klar S, Butt G, Nijkamp MD, Buxton JA. “It's a big part of our lives”: a qualitative study defining quality of hepatitis C care from the patient's perspective. Gastroenterol Nurs. 2013;36(4):249–57.PubMedCrossRef
87.
go back to reference Dawood M, Smart G, Wood M, Wu HX, Paton S, Wu J. Hepatitis C virus infection among first nation and non-first nation people in Manitoba, Canada—a public health laboratory study. Can J Microbiol. 2006;52(10):999–1005.PubMedCrossRef Dawood M, Smart G, Wood M, Wu HX, Paton S, Wu J. Hepatitis C virus infection among first nation and non-first nation people in Manitoba, Canada—a public health laboratory study. Can J Microbiol. 2006;52(10):999–1005.PubMedCrossRef
Metadata
Title
Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment
Authors
Caroline O’Keefe-Markman
Kristina Dawn Lea
Christopher McCabe
Elaine Hyshka
Tania Bubela
Publication date
01-12-2020
Publisher
BioMed Central
Keywords
Care
Hepatitis C
Published in
BMC Public Health / Issue 1/2020
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-020-8190-2

Other articles of this Issue 1/2020

BMC Public Health 1/2020 Go to the issue